Physician profile
Brant Harber
NPI 1225619232
$1,066.65
in general payments reported to CMS, 2019-2025
11 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $576 · 2024: $240 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $128.84 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $121.82 | 2025 | Fasenra |
| Kyowa Kirin, INC. | $121.81 | 2024 | Crysvita |
| Edwards Lifesciences Corporation | $119.11 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $117.32 | 2023 | |
| Glaxosmithkline, LLC. | $108.90 | 2023 | Arexvy |
| Tactile Systems Technology INC | $101.45 | 2023 | Flexitouch Plus, Entre Plus |
| Novo Nordisk INC | $83.46 | 2023 | Wegovy |
| Tris Pharma INC | $83.19 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Idorsia Pharmaceuticals US INC | $46.24 | 2023 | Quviviq |
| Neurelis, INC. | $34.51 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brant Harber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.